Q-omics provides the consensus-scored YPEL5P2 profile across patient tissues and cancer cell-line models. YPEL5P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, YPEL5P2 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, YPEL5P2 RNA expression shows 13,172 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where YPEL5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YPEL5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YPEL5P2 survival associations across molecular data types. YPEL5P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YPEL5P2 RNA expression–survival associations across cancer types. High YPEL5P2 expression shows unfavorable associations in ACC, UCEC and KICH, but favorable associations in BRCA, UCS and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for YPEL5P2 RNA expression.
This table summarizes YPEL5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for YPEL5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YPEL5P2 shows lower tumor expression in THCA and higher tumor expression in COAD, LUSC, CHOL and LIHC. The COAD box plot shows higher YPEL5P2 RNA expression in tumor versus normal tissue (log2 FC = +0.274, t-test p < 0.001).
This table shows molecular features associated with YPEL5P2 in patient tissues and cancer cell lines. In patient samples, YPEL5P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
